Filing Details
- Accession Number:
- 0000950170-24-057456
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-10 07:30:19
- Reporting Period:
- 2024-05-08
- Accepted Time:
- 2024-05-10 07:30:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1095981 | Plus Therapeutics Inc. | PSTV | Surgical & Medical Instruments & Apparatus (3841) | 330827593 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1802687 | Macintyre Hugh John Andrew Sims | C/O Plus Therapeutics Inc. 4200 Marathon Boulevard, Suite 200 Austin TX 78756 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-05-08 | 4,902 | $2.04 | 5,717 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock Warrants | Warrants (Right to buy) | Acquisiton | 2024-05-08 | 9,804 | $0.00 | 9,804 | $1.79 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,804 | 2024-05-08 | No | 4 | A | Direct |
Footnotes
- The expiration date for 4,902 of the warrants (Series A warrants) is May 8, 2029. The expiration date for the other 4,902 warrants (Series B warrants) is the one-year anniversary of the effectiveness of a registration statement covering the resale of shares of common stock underlying the Series B warrants.
- Half of the warrants are Series A warrants and the other half are Series B warrants.